{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:45Z","timestamp":1791902685913,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40257-024-00899-4","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T06:02:19Z","timestamp":1729663339000},"page":"109-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b\/3 Randomized Clinical Trial"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"nct03732807","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rodney","family":"Sinclair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjali","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Wajsbrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest H.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"899_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14:81\u20139.","journal-title":"Autoimmun Rev"},{"key":"899_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82:675\u201382.","journal-title":"J Am Acad Dermatol"},{"key":"899_CR3","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20:S62\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"899_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","volume":"88","author":"JP Okhovat","year":"2023","unstructured":"Okhovat JP, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2023;88:1040\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"899_CR5","unstructured":"United States Food and Drug Administration. Patient-focused drug development public meeting for alopecia areata. 2017. Accessed 4 Apr 2024."},{"issue":"4","key":"899_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"11","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, Kitchen H, Knight S, Macey J, Nunes FP, Dutronc Y, et al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;11(4):76.","journal-title":"J Patient Rep Outcomes."},{"key":"899_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85:162\u201375.","journal-title":"J Am Acad Dermatol"},{"key":"899_CR8","doi-asserted-by":"crossref","unstructured":"Marahatta S, Agrawal S, Adhikari BR. Psychological impact of alopecia areata. Dermatol Res Pract. 2020;2020:8879343.","DOI":"10.1155\/2020\/8879343"},{"key":"899_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79:556-8.e1.","journal-title":"J Am Acad Dermatol"},{"key":"899_CR10","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687\u201399.","journal-title":"N Engl J Med"},{"key":"899_CR11","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401:1518\u201329.","journal-title":"Lancet"},{"key":"899_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"A Finlay","year":"1994","unstructured":"Finlay A, Khan G. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"899_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","volume":"107","author":"MM Chren","year":"1996","unstructured":"Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707\u201313.","journal-title":"J Invest Dermatol"},{"key":"899_CR14","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1111\/j.1468-3083.2012.04629.x","volume":"27","author":"G Fabbrocini","year":"2013","unstructured":"Fabbrocini G, Panariello L, De Vita V, Vincenzi C, Lauro C, Nappo D, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol. 2013;27:e276\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"899_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1684\/ejd.2012.1752","volume":"22","author":"Y Endo","year":"2012","unstructured":"Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol. 2012;22:531\u20136.","journal-title":"Eur J Dermatol"},{"key":"899_CR16","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jisp.2017.10.009","volume":"19","author":"TR Mendoza","year":"2018","unstructured":"Mendoza TR, Osei J, Duvic M. The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning. J Investig Dermatol Symp Proc. 2018;19:S41\u20136.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"899_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13555-021-00648-z","volume":"12","author":"K Wyrwich","year":"2022","unstructured":"Wyrwich K, Winnette R, Bender R, Gandhi K, Williams N, Harris N, et al. Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther (Heidelb). 2022;12:149\u201366.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"899_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-021-00508-w","volume":"11","author":"R Winnette","year":"2021","unstructured":"Winnette R, Martin S, Harris N, Deal L. Development of the Alopecia Areata Patient Priority Outcomes instrument: a qualitative study. Dermatol Ther (Heidelb). 2021;11:1\u201315.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"899_CR19","doi-asserted-by":"crossref","unstructured":"Sinclair R, Law E, Zhang X, Zhang F, Napatalung L, Zwillich S, et al. Patient-reported satisfaction with hair regrowth in a study of ritlecitinib in alopecia areata: results from ALLEGRO-2b\/3. Dermatology. 2024:1\u201311. (Online ahead of print).","DOI":"10.1159\/000539536"},{"key":"899_CR20","first-page":"397","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"899_CR21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, Winnette R, Xenakis J, Zwillich SH, et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb). 2021;11:867\u201383.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"899_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamadermatol.2022.6085","volume":"159","author":"S Lauron","year":"2023","unstructured":"Lauron S, Plasse C, Vaysset M, Pereira B, D\u2019Incan M, Rondepierre F, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2023;159:281\u20138.","journal-title":"JAMA Dermatol"},{"key":"899_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bmj.331.7522.951","volume":"331","author":"N Hunt","year":"2005","unstructured":"Hunt N, McHale S. The psychological impact of alopecia. BMJ. 2005;331:951\u20133.","journal-title":"BMJ"},{"key":"899_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/ijt.ijt_99_20","volume":"12","author":"LJ Burns","year":"2020","unstructured":"Burns LJ, Mesinkovska N, Kranz D, Ellison A, Senna MM. Cumulative life course impairment of alopecia areata. Int J Trichol. 2020;12:197\u2013204.","journal-title":"Int J Trichol."},{"key":"899_CR25","doi-asserted-by":"crossref","unstructured":"King B, Bergfeld W, Brzewski P, A\u015fk\u0131n \u00d6, Passeron T, Randhawa S, et al. Impact of disease history on the efficacy of ritlecitinib (PF-06651600) in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b\/3 study. In: 31st Annual Congress of the European Academy of Dermatology and Venerology (EADV). 2022.","DOI":"10.25251\/skin.6.supp.101"},{"key":"899_CR26","unstructured":"Piliang M, Soung J, King B, Shapiro J, Rudnicka L, Farrant P, et al. Efficacy and safety of the oral JAK3\/TEC family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase 2b\/3 and long-term phase 3 clinical studies in alopecia areata. Br J Dermatol. In Press."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00899-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00899-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00899-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T07:48:41Z","timestamp":1737100121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00899-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00899-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"25 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer Inc. The sponsor, Pfizer Inc, was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript for publication. Medical writing and editorial support provided by Nucleus Global were funded by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"R.S. reports professional services for AbbVie, Acrotech, Amgen, Arena, Arcutis, Aksebio, AstraZeneca, Ascend, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus BioSciences, Cutanea, Connect, Demira, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, MedImmune, Merck, MSD, Novartis, Oncobiologics, Pfizer, Regeneron, Reistone, Roche, Sanofi, Samson Clinical, SUN Pharma, and UCB. N.M. reports professional services for AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Concert Pharmaceuticals, Eli Lilly, La Roche-Posay, and Pfizer. D.M., D.W., E.H.L., and R.W. are employees of or hold stock or stock options in Pfizer Inc. B.K. has received honoraria and\/or consultation fees from AbbVie, AltruBio, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte, Janssen Pharmaceuticals, LEO Pharma, Otsuka\/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio. He has previously served on speaker bureaus for AbbVie, Incyte, Eli Lilly, Pfizer, Regeneron, and Sanofi Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See  for more information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This study was approved by the institutional review boards or ethics committees of the participating institutions. The study was conducted in accordance with the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), ICH Guideline for Good Clinical Practice, and the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each patient, parent, or the patient\u2019s legal representative.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"E.H.L. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript. Conceptualization:\u00a0D.M., D.W., E.H.L., R.W. Data curation:\u00a0R.S., N.M., D.M., D.W., E.H.L, R.W., B.K. Writing\u2014original draft:\u00a0E.H.L. Writing\u2014review and editing:\u00a0R.S., N.M., D.M., D.W., E.H.L., R.W., B.K. Formal analysis:\u00a0D.W.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}